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The National Technical Advisory Group on Immunisation in India (NTAGI) fulﬁls a need for informing
decision-making concerning the introduction of new vaccines and strengthening the Universal Immu-
nisation Programme (UIP). The role and membership of NTAGI have expanded over the years in tune
with the emerging needs and priorities of the Government of India. Current challenges include institu-
tionalizing mechanisms to follow-up and monitor recommendations, to support research needs to ﬁll
provi
 information gaps, and to
. Description and background
India adopted the Expanded Programme on Immunisation (EPI)
n 1978, targeting 80% coverage of infants with Bacillus Calmette-
uérin, diphtheria, tetanus andpertussis vaccine, oral polio vaccine
nd typhoid–paratyphoid (whole cell, killed) vaccine. EPI was
evised as the Universal Immunisation Programme (UIP) during
985–1990, targeting 100% coverage; also typhoid–paratyphoid
accine was dropped and measles vaccine was added. Tetanus
oxoid vaccination of pregnant women was part of EPI and was
etained in UIP.
TheUIP ismanaged by two senior ofﬁcers (Deputy andAssistant
ommissioners) in the Immunisation Division of the Department
f Family Welfare (DFW) under the Ministry of Health and Family
elfare (MoHFW) of the Government of India (GoI). The func-
ional responsibility is sharedbetweenGoI and StateGovernments:
oI provides funds, policy formulation, training of staff, cold chain
upport and procurement and supply of vaccines and injection
quipmentwhile the States are responsible for the implementation
f the program.
Earlier, there was no mechanism established within EPI/UIP for
egular technical reviews. When technical inputs were required,
d hoc consultations with experts (identiﬁed on the basis of
ssues needing to be discussed) were undertaken. In 1985, measles
accine was introduced as recommended by the Planning Com-
Abbreviations: EPI, Expanded Programme on Immunisation; DFW, Department
f Family Welfare; GoI, Government of the India; MoHFW, Ministry of Health and
amily Welfare; NTAGI, National Technical Advisory Group on Immunisation; TOR,
erms of Reference; UIP, Universal Immunisation Programme; WHO, World Health
rganization.
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mission under the 7th Five-year Economic Plan. From about that
time it had been recognized that there was a need for a mecha-
nism for continuous and sustained availability of technical inputs
regarding implementation of the vaccination program, regulatory
aspects, new vaccine introduction as well as for research. To ﬁll
this need, the National Technical Advisory Group on Immunisa-
tion (NTAGI) was established in August 2001 by the DFW [1]. The
NTAGIwas intended toprovide technical advice to informdecision-
making on both technical and operational matters pertaining to
immunisation and choice and scheduling of existing and planned
vaccines.
The NTAGI thus is meant to be the primary advisory committee
(hereafter also referred to as the Committee) advising the MoHFW
on all immunisation-related issues. The Ofﬁce Order, issued by the
Ministry in August of 2001 to constitute the NTAGI, designated
the Secretary to the GoI (in the Department of Health Services
and DFW) to be its Chair and the Deputy Commissioner (Immu-
nisation Division) as its Member-Secretary. It had representation
from a wide spectrum of relevant constituencies (Table 1). They
included national organizations involved in health-care policy and
research, such as the Indian Council of Medical Research and the
National Institute of Health and Family Welfare; professional orga-
nizations such as the Indian Academy of Paediatrics and the Indian
Medical Association; representatives of GoI agencies such as the
ChildHealthDivision,DepartmentofBiotechnology, PlanningCom-
mission, and the National Regulatory Authority (Drugs Controller
General of India); representatives of ﬁve State Governments (Mad-
hya Pradesh, Maharashtra, Orissa, Tamil Nadu and Uttar Pradesh);
and ﬁve independent experts. Although not formal members, rep-
resentatives of UNICEF, the World Health Organization (WHO) and
Open access under CC BY-NC-ND license.theWorld Bank are invited to attend committeemeetings. Care has
been taken formembers to represent a range of expertise including
pediatricians, epidemiologists, public health specialists, infectious
disease experts, virologists/microbiologists, vaccinologists, immu-
nisation programme experts, logisticians and regulatory experts.
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Table 1
Members of the National Technical Advisory Group on Immunisation constituted in
August 2001with the approval of the Secretary of theDepartment of FamilyWelfare
(DFW), Government of India.
Chairman
Secretary (DFW)
Members:
Department of Family Welfare
Joint Secretary (Maternal and Child Health)
Deputy Commissioner (Immunisation)
Assistant Commissioner (Universal Immunisation Programme)
Representative of National Organizations
Indian Council of Medical Research
National Institute of Virology, Pune
National Institute of Communicable Disease, Delhi
National Institute of Health and Family Welfare
National Institute of Immunology, Delhi
Representatives of Professional Organizations
Indian Academy of Pediatrics
Indian Medical Association
Indian Association of Preventive and Social Medicine
State Government Representatives/Program managers
Secretary (DFW), Orissa
Secretary (DFW), Uttar Pradesh
State Director/State RCH Ofﬁcer, Tamil Nadu
Director (DFW), Maharashtra
Director (DFW), Madhya Pradesh
Representatives of Government Departments
Department of Women and Child Development
Internal Finance Division, Ministry of Health and Family Welfare
Department of Bio-Technology
Planning Commission
Drug Controller General of India
Experts
Dr. Jacob John
Dr. Ranjit Rai Choudhary
Dr. Shanti Ghosh
Dr. K.B. Banerjee
Dr. Jotna Sokhey
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3Representative from UNICEF
Representative from World Health Organization
Representative from World Bank
ne independent expert is mandated to function as Co-chair of the
TAGI.
The NTAGI is essentially a standing committee under the DFW
n the MoHFW. As a specially established committee its ofﬁcial
dministrative position and status within the GoI is unclear,
xcept that it was created by a formal Ofﬁce Order from MoHFW.
he current membership and Terms of Reference (TOR) of the
nitial NTAGI (2001) are detailed in Tables 1 and 2. While non-
overnment members are paid expenses to attend meetings,
o remuneration is paid to government employees. So far no
equirement for members to declare actual or potential conﬂicts of
nterest has been deﬁned. However, members have been selected
n the basis of a reputation for integrity in addition to expertise.
ndustry representatives may be invited to present data but they
o not participate in other discussions. The development of a tool
o ensure lack of, or to document any speciﬁc, conﬂict of interests
s being considered for the future.
. Operation of the NTAGI
The ﬁrst meeting of the NTAGI was on 19 December 2001 with
he following objectives:
. Identiﬁcation of reasons for declining immunisation coverage.
. Involvement of the private sector to improve coverage levels.
. Plans for expansion of the cold chain system.2010) A88–A90 A89
4. Standardized monitoring and evaluation of the UIP.
5. Setting criteria for the introduction of new vaccines.
6. Identiﬁcation of research needs.
Based on deliberations at this ﬁrst meeting, it was decided that
sub-groups would be established to examine the following speciﬁc
issues:
1. Operational issues including injection safety.
2. Monitoring and surveillance.
3. Introduction of new vaccines.
4. Vaccine quality and coordination with the National Regulatory
Authority.
5. Research needs—future studies.
3. Meeting schedules and format
In its early years the NTAGI met infrequently, but currently it
meets more often (see below). The Immunisation Division acts as
theSecretariat for schedulingmeetings, preparingminutes and tak-
ing follow-up actions. The meeting agenda is based on the needs
of the Immunisation Division as well as requests from the States.
Meetings are “close-door” with additional observers attending by
invitation only. However, the NTAGI has the ability to invite or co-
opt experts in speciﬁc ﬁelds according to need and the topics to be
discussed. Manufacturers of vaccines do not play any role in NTAGI
but have been invited on occasion. The decisions (resolutions) and
recommendations of the NTAGI are reached by general agreement
among members and Chair and to date there has been no need for
members to vote.
On an ad hoc basis, NTAGI sub-groups and Expert Advisory
Groups (outside NTAGI) are constituted through the Secretariat
to address speciﬁc issues and to submit their summary assess-
ments, suggestions and recommendations. In addition, the existing
disease-speciﬁc working groups on measles and polio estab-
lished through ‘Partner Networks’ (WHO, UNICEF, and other
bilateral/international agencies) may forward their recommenda-
tions to the NTAGI for consideration.
For recommendations regarding the introduction of a new vac-
cine into the UIP, the NTAGI may directly make resolutions, or
assign the task to a Sub-group to bring its proposals to the NTAGI
meeting. Thedecision-makingprocess is based ondisease epidemi-
ology, disease burden, cost-effectiveness analyses and priority of
vaccine introduction related to other public health interventions.
When data are inadequate, the opinions of experts and the collec-
tive wisdom of the members may be applied.
4. Evolution of NTAGI
Since its formation in August 2001, the NTAGI has met six times
(December 2001, October 2004, March 2006, July 2007, June 2008
and August 2009). A number of important interventions, namely
introduction of vaccines against Japanese encephalitis, hepatitis B,
rubella (in combinationwith a second opportunity formeasles vac-
cine, as measles rubella vaccine) and Haemophilus inﬂuenzae type
b (as a combination pentavalent vaccine) and introduction of auto-
disable syringes in the UIP, were recommended by the NTAGI and
have been accepted by the MoHFW [2].
More recently the NTAGI has made extensive deliberations on
several issues—development of a Multi-Year Strategic Plan for the
UIP (GoI, 2002–2007), the pros and cons of introduction of rotavirus
and pneumococcal vaccines, enhanced measles control activities,
the safety of thiomersal in vaccines, introduction of vaccine vial
monitors on all vaccine vials, review of the human resource needs
for immunisation at GoI and State levels and the re-engineering
of the UIP as a system. For several issues the NTAGI has made
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Table 2
Major roles and terms of reference of the National Technical Advisory Group on Immunisation in India.
Major roles
To be an advisory body to assist the Government of India in developing a nation-wide policy framework for vaccines and immunisation
To prioritize immunisation activities and set attainable targets
Identify critical gaps in policy and programme and identify studies, assessment and research areas to be addressed
To review periodic assessment of the national immunisation programme, including immunisation performance and disease incidence
Terms of reference
Identify reasons for the decline in immunisation coverage levels, identify bottlenecks and suggest measures to revitalize the routine immunisation activities
Establish criteria for ensuring a cost effective expansion/renewal plan for the cold chain
Set up norms for periodic evaluation of the immunisation programme (e.g., frequency surveys, methodology to be adopted, and mechanism for data
dissemination)
Examine the current status of surveillance under the Reproductive and Child Health Programme and suggest mechanism for integrating the National Polio
Surveillance Project network with the existing surveillance system once the polio is eradicated
Firm up guideline for epidemic/outbreak control measures for vaccine-preventable diseases
Establish standards and criteria for introduction of new vaccines under the Universal Immunisation Programme
Guide policy for introduction of injection safety technology into the immunisation programme
Suggest innovative strategies for introducing demand generation strategies in the programme
Examine the role of private sector vis-a-vis immunisation and suggest measures for a more effective programme with private sector partnership
Identify strategies, which would be required under special circumstances for instance (a) in under served areas like urban slums and tribal areas (b)
immunisation during natural calamities
Identify areas that need research studies including cost effectiveness analysis, burden of diseases studies, operations research, etc., and suggest modalities
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Suggest mechanisms and modalities for improving the vaccine quality assuranc
India)
Examine the need for decentralization of programme implementation and sugg
peciﬁc recommendations, many of which have been acted on by
he MoHFW. On some issues, the recommendations are still being
onsidered.
Over the years, the role of the NTAGI (and consequently the
embership) has evolved to meet the changing requirements
t the national level. Other issues pertaining to immunisa-
ion have also been taken up for ongoing discussions such
s improving coverage and access, promoting vaccine secu-
ity, monitoring of adverse events following vaccinations,
accines beyond childhood (like human papilloma virus, sea-
onal inﬂuenza and meningitis vaccines), public–private part-
erships in the UIP, and measuring and monitoring the
mpact of immunisations. Currently, the minutes and recom-
endations (http://mohfw.nic.in/dofw%20website/june.pdf) of the
TAGI are published on the MoHFW website (http://mohfw.
ic.in/dofw%20website/dofw.htm), to promote transparency and
acilitate access to everyone. At the lastmeeting of theNTAGI itwas
esolved to increase the frequency of meetings to twice annually
nitially, progressing to meeting every quarter.
. Future directions and challenges
Recognizing the need to strengthen the functioning of the
TAGI, a number of issues have been proposed. The need for reg-
lar meetings of the NTAGI has been clear. Earlier meetings were
nnounced on an ad hoc basis but in the future meetings are to be
re-scheduled. This will help to strengthen the NTAGI as an insti-
ution and to allow better monitoring of the implementation of
ecommendations. To achieve these goals the NTAGI has a critical
eed for full-time support services to provide a secretariat, as well
s technical assistance for data review and developing norms and
tandards. A mechanism and funding for generating data (e.g., dis-
ase burden, vaccine efﬁcacy, and cost effective studies) are needed
o support the NTAGI’s decision-making and recommendations.
ince health personnel are the backbone of the immunisation pro-
ram, there is a critical need for the NTAGI to widen its scope to
nclude human resource issues in its agenda. Similarly, the exper-
ise of the NTAGI may be used to monitor the progress of the UIP
s well as to deliberate and provide recommendations on other
mportant issues for strengthening childhood immunisation like
mprovingaccess andcoverage; optimizingutilizationof resources;
trengtheningmonitoringandsupervision; reducing immunisation
[
[ugh the National Regulatory Authority (Drug Controller General of
e degree and modalities for affecting the same
drop out rates by tracking children through full immunisation; and
strengthening the surveillance of vaccine-preventable diseases and
adverse events following immunisation.
6. Conclusion
The NTAGI has evolved from an ad hoc decision-making pro-
cess to one that is transparent, collective and systematic using the
best available evidence for decision-making. However, wide gaps
between the available and optimal evidence required have been
noted. This has occurred in part because available evidence often
comes from research thatwas not necessarily conducted to provide
speciﬁc data to inform decisions such as on the choice of vaccines
and their inclusion in theUIP. Amore serious gap is the lackof quan-
titative data on the frequency of diseases or mortality from the GoI
agencies concernedwith disease control, such as theNational Insti-
tute of Communicable Diseases and the Central Bureau of Health
Intelligence.
Recently there has been debate in localmedical journals regard-
ing the Indian NTAGI recommendations, e.g., the recommendation
for a phased introduction of the combination pentavalent vac-
cine. This is seen as a healthy trend. Major weaknesses in the
UIP remain that affect its efﬁciency. These include: the time taken
by national and state governments to implement NTAGI recom-
mendations; lack of an institutional mechanism to follow-up and
monitor recommendations; and differing perceptions about the
respective roles and responsibilities of GoI, State Governments and
other stakeholders. The lack of comprehensive data on disease bur-
den and the lack of surveillance systems for vaccine-preventable
diseases add to the difﬁculty that India has in achieving the full
potential of its Immunisation Division.
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